David Simon, DO
Family Medicine · Lake Worth, FLNPI 1912979279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $851 and has fallen 72.0% since, to $238 in 2025.
Across 178 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$462
- Supernus Pharmaceuticals, Inc.$278
- Johnson & Johnson$267
- Collegium Pharmaceutical, Inc.$259
- Pfizer$231
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$225
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,19295%
- Education$1795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $462 |
| Supernus Pharmaceuticals, Inc. | 15 | $278 |
| Johnson & Johnson | 9 | $267 |
| Collegium Pharmaceutical, Inc. | 15 | $259 |
| Pfizer | 12 | $231 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $225 |
| Astellas Pharma US Inc | 3 | $194 |
| AstraZeneca | 11 | $176 |
| Novo Nordisk | 10 | $171 |
| Merck | 8 | $136 |
| Eisai Inc. | 7 | $101 |
| Kowa Pharmaceuticals America, Inc. | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $73 |
| Orexo US, Inc. | 4 | $73 |
| Exact Sciences | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $59 |
| GSK | 3 | $53 |
| Amgen | 2 | $36 |
| Adlon Therapeutics L.p. | 2 | $32 |
| Lilly USA, LLC | 2 | $30 |
| Bayer | 1 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Forte Bio-pharma LLC | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,371 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $56,215 |
| OzempicSemaglutide | 24 | $28,013 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,201 |
| RybelsusSemaglutide | 17 | $22,652 |
| XareltoRivaroxaban | 12 | $14,338 |
| MyrbetriqMirabegron | 15 | $10,299 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 51 | $7,943 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 199 | $6,040 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 123 | $4,327 |
| Oxycodone Hcl | 153 | $3,586 |
| Morphine Sulfate ErMorphine Sulfate | 56 | $2,476 |
| Lisdexamfetamine Dimesylate | 11 | $2,302 |
| Alprazolam | 347 | $1,786 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,546 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $231 | $56,21562 claims |
| Novo NordiskOzempic, Rybelsus | $171 | $50,66541 claims |
| GSKTrelegy Ellipta | $53 | $25,20130 claims |
| Johnson & JohnsonXarelto | $267 | $14,33812 claims |
| Astellas Pharma US IncMyrbetriq | $194 | $10,29915 claims |
| AbbVieSynthroid | $462 | $1,30911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lake Worth
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.